Peyton Greenside, the CEO of BigHat Biosciences based in San Mateo, California, has voiced her opinions on the hype surrounding AI in drug development. While her company utilizes machine learning to design antibody therapies, she cautions against the oversimplification of the drug development process. Greenside can design a protein in just 20 minutes, but she emphasizes that the real challenge lies in the extensive downstream testing required to bring a drug to market, which is both time-consuming and costly. Founded in 2019, BigHat has made significant strides in the biotech field, having successfully collaborated with Johnson & Johnson and established partnerships with other major firms such as Merck, Amgen, and Abbvie. The company has a unique tradition of hanging a hat on the wall for each completed project, symbolizing its achievements. Greenside's insights highlight the need for a realistic understanding of the role of AI in drug development, moving beyond mere demonstrations of speed to address the complexities involved in creating effective therapies.